TNF-alpha adalimumab mechanism

Adalimumab neutralizes TNF-alpha

Adalimumab functions through five complementary mechanisms to inhibit TNF-alpha activity. Structurally, adalimumab binds TNF-alpha with high affinity (KD 7.05-10 × 10⁻¹¹ M) through a large epitope (2,540 Ų buried surface area) that directly occupies the TNF receptor-binding site, blocking both soluble and transmembrane TNF-alpha. Beyond neutralization, adalimumab induces cytotoxic effects including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and caspase-3-mediated apoptosis in transmembrane TNF-alpha-expressing cells. Adalimumab modulates intracellular signaling by reversing NF-κB pathway activation and downregulating genes including IKBKB, IRAK1, TRAF2, and MAP3K7, while simultaneously regulating anti-inflammatory microRNAs (miR-1297, miR-30a, miR-126-3p) and pro-inflammatory microRNAs (miR-146a-5p).

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

Screening Criteria

• Mechanistic Focus: Study investigates adalimumab’s mechanism of action in TNF-alpha inhibition.
• Mechanistic Measurements: Measuring biomarkers related to TNF-alpha inhibition.
• Study Design: Type of study: in vitro, in vivo, human study, or systematic review/meta-analysis.
• Adalimumab Population: Involves patients treated with adalimumab.
• Mechanistic Investigation: Includes mechanistic insights beyond clinical efficacy or safety outcomes.
• Adalimumab-Specific Data: Includes adalimumab-specific data.
• Mechanistic Insights: Provides mechanistic insights beyond pharmacokinetics or pharmacodynamics.
• Publication Type: Is a peer-reviewed research article or systematic review.

Key Mechanistic Findings

• Binding Characteristics: Adalimumab binds TNF-alpha effectively via multiple epitope segments.
• Cytotoxic Mechanisms: Induces apoptosis in transmembrane TNF-alpha-expressing cells through multiple pathways.
• Target Cells/Tissues: Explores effects on immune cells and endothelial function.

Clinical Implications

Therapeutic Efficacy Mechanisms

• Mechanism Explanation: Steric blocking of TNF-alpha contributes to therapeutic efficacy.
• Biomarker Potential: NF-κB-associated miRNAs show potential for monitoring treatment response.

Resistance Mechanisms

• Anti-adalimumab antibodies present a critical resistance mechanism.

Comparative Mechanisms Among Anti-TNF Agents

Adalimumab demonstrates a larger antigen-antibody interface than infliximab and unique complex-forming capacity unlike etanercept. Both adalimumab and infliximab induce apoptosis and cell cycle arrest.

Synthesis

Adalimumab’s mechanisms involve direct TNF-alpha sequestration, cytotoxic elimination of TNF-alpha-expressing cells, and modulation of intracellular signaling and epigenetic regulation through microRNAs. These mechanisms explain adalimumab’s advantages over other anti-TNF agents.